ATE352636T1 - Auf dem rinderimmunschwächevirus (biv) basierte vektoren - Google Patents

Auf dem rinderimmunschwächevirus (biv) basierte vektoren

Info

Publication number: ATE352636T1
Authority: AT; Austria
Prior art keywords: biv; gene; vectors; operably linked; packaging
Prior art date: 1999-12-14

Application number

AT00986343T

Other languages

English (en)

Inventor

Tianci Luo

Robert David Berkowitz

Michael Kaleko

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-14

Filing date

2000-12-13

Publication date

2007-02-15

2000-12-12 Priority claimed from US09/734,836 external-priority patent/US6864085B2/en

2000-12-13 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2007-02-15 Application granted granted Critical

2007-02-15 Publication of ATE352636T1 publication Critical patent/ATE352636T1/de

Links

239000013598 vector Substances 0.000 title abstract 7
241000713704 Bovine immunodeficiency virus Species 0.000 title 2
108020004414 DNA Proteins 0.000 abstract 4
239000012634 fragment Substances 0.000 abstract 3
238000004806 packaging method and process Methods 0.000 abstract 3
108090000623 proteins and genes Proteins 0.000 abstract 2
102000018697 Membrane Proteins Human genes 0.000 abstract 1
108010052285 Membrane Proteins Proteins 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
108700019146 Transgenes Proteins 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
108700004026 gag Genes Proteins 0.000 abstract 1
101150098622 gag gene Proteins 0.000 abstract 1
210000004962 mammalian cell Anatomy 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
108700004029 pol Genes Proteins 0.000 abstract 1
101150088264 pol gene Proteins 0.000 abstract 1
230000008488 polyadenylation Effects 0.000 abstract 1
210000002845 virion Anatomy 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Virology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT00986343T 1999-12-14 2000-12-13 Auf dem rinderimmunschwächevirus (biv) basierte vektoren ATE352636T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46446099A	1999-12-14	1999-12-14
US24949200P	2000-11-17	2000-11-17
US09/734,836 US6864085B2 (en)	1999-12-14	2000-12-12	Bovine immunodeficiency virus (BIV) based vectors

Publications (1)

Publication Number	Publication Date
ATE352636T1 true ATE352636T1 (de)	2007-02-15

Family

ID=27400217

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT00986343T ATE352636T1 (de)	1999-12-14	2000-12-13	Auf dem rinderimmunschwächevirus (biv) basierte vektoren
AT07001113T ATE458062T1 (de)	1999-12-14	2000-12-13	Auf bovinem immundefizienvirus (biv) basierende vektoren

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT07001113T ATE458062T1 (de)	1999-12-14	2000-12-13	Auf bovinem immundefizienvirus (biv) basierende vektoren

Country Status (10)

Country	Link
EP (2)	EP1852511B1 (de)
JP (3)	JP2003517312A (de)
AT (2)	ATE352636T1 (de)
AU (1)	AU778110B2 (de)
CA (1)	CA2392221C (de)
DE (2)	DE60043870D1 (de)
ES (2)	ES2340073T3 (de)
IL (2)	IL149704A0 (de)
NZ (1)	NZ519034A (de)
WO (1)	WO2001044458A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2170622B1 (es)	1999-12-03	2004-05-16	Consejo Superior De Investigaciones Cientificas	Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
NZ519034A (en) *	1999-12-14	2005-02-25	Novartis Ag	Bovine immunodeficiency virus (BIV) based vectors
US7575924B2 (en)	2000-11-13	2009-08-18	Research Development Foundation	Methods and compositions relating to improved lentiviral vectors and their applications
IL157335A0 (en)	2001-03-13	2004-02-19	Novartis Ag	Lentiviral packaging constructs
ATE527347T1 (de)	2001-08-02	2011-10-15	Inst Clayton De La Rech	Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
RU2305708C2 (ru)	2001-10-02	2007-09-10	Энститю Клейтон Де Ля Решерш	Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
ES2208051B1 (es) *	2002-01-24	2005-08-16	Consejo Sup. Investig. Cientificas	Secuencia de acido nucleico que comprende la señal de encapsidacion del rna de un coronavirus del grupo 1 y sus aplicaciones.
JP2005533485A (ja) *	2002-02-04	2005-11-10	ノバルティスアクチエンゲゼルシャフト	組換えウシ免疫不全ウイルスに基づく遺伝子導入システム
GB2450688A (en) *	2005-05-11	2009-01-07	Viragen Inc	Ovalbumin promoter constructs for retroviral vectors
JP6509884B2 (ja) *	2014-01-30	2019-05-08	チルドレンズホスピタルメディカルセンター	鎌状赤血球病の遺伝子的是正のための改善された胎児ヘモグロビン
GB202114532D0 (en) *	2021-10-12	2021-11-24	Oxford Biomedica Ltd	Lentiviral Vectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5380830A (en) *	1989-09-18	1995-01-10	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Molecular clones of bovine immunodeficiency-like virus
US6013516A (en) *	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
FR2768743B1 (fr)	1997-09-23	2001-09-14	Bio Merieux	Procede de lyse de micro-organisme
CA2304983A1 (en) *	1997-09-24	1999-04-01	The Regents Of The University Of California	Non-primate lentiviral vectors and packaging systems
DE69941049D1 (de) *	1998-05-22	2009-08-13	Oxford Biomedica Ltd	Retrovirales verabreichungssystem
NZ519034A (en) *	1999-12-14	2005-02-25	Novartis Ag	Bovine immunodeficiency virus (BIV) based vectors

2000
- 2000-12-13 NZ NZ519034A patent/NZ519034A/en not_active IP Right Cessation
- 2000-12-13 ES ES07001113T patent/ES2340073T3/es not_active Expired - Lifetime
- 2000-12-13 CA CA2392221A patent/CA2392221C/en not_active Expired - Fee Related
- 2000-12-13 JP JP2001545535A patent/JP2003517312A/ja active Pending
- 2000-12-13 DE DE60043870T patent/DE60043870D1/de not_active Expired - Lifetime
- 2000-12-13 EP EP07001113A patent/EP1852511B1/de not_active Expired - Lifetime
- 2000-12-13 AT AT00986343T patent/ATE352636T1/de active
- 2000-12-13 AT AT07001113T patent/ATE458062T1/de not_active IP Right Cessation
- 2000-12-13 IL IL14970400A patent/IL149704A0/xx unknown
- 2000-12-13 DE DE60033180T patent/DE60033180T2/de not_active Expired - Lifetime
- 2000-12-13 ES ES00986343T patent/ES2281369T3/es not_active Expired - Lifetime
- 2000-12-13 EP EP00986343A patent/EP1238092B1/de not_active Expired - Lifetime
- 2000-12-13 AU AU22598/01A patent/AU778110B2/en not_active Ceased
- 2000-12-13 WO PCT/US2000/033725 patent/WO2001044458A2/en not_active Ceased
2002
- 2002-05-16 IL IL149704A patent/IL149704A/en not_active IP Right Cessation
2010
- 2010-02-26 JP JP2010043354A patent/JP2010166919A/ja active Pending
2013
- 2013-12-24 JP JP2013265269A patent/JP2014110789A/ja active Pending

Also Published As

Publication number	Publication date
DE60033180D1 (de)	2007-03-15
EP1852511A1 (de)	2007-11-07
IL149704A (en)	2013-02-28
CA2392221A1 (en)	2001-06-21
AU2259801A (en)	2001-06-25
ES2340073T3 (es)	2010-05-28
EP1238092A2 (de)	2002-09-11
ATE458062T1 (de)	2010-03-15
ES2281369T3 (es)	2007-10-01
CA2392221C (en)	2012-01-31
AU778110B2 (en)	2004-11-18
WO2001044458A3 (en)	2001-11-29
NZ519034A (en)	2005-02-25
EP1238092B1 (de)	2007-01-24
JP2014110789A (ja)	2014-06-19
WO2001044458A2 (en)	2001-06-21
DE60033180T2 (de)	2007-10-25
IL149704A0 (en)	2002-11-10
JP2003517312A (ja)	2003-05-27
JP2010166919A (ja)	2010-08-05
EP1852511B1 (de)	2010-02-17
DE60043870D1 (de)	2010-04-01

Legal Events

Date

Code

Title

Description

2007-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1238092

Country of ref document: EP

Publication	Publication Date	Title
Garcia-Sastre et al.	1994	Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus
Binley et al.	2002	Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins
Pinter et al.	1997	Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes
RU2733832C1 (ru)	2020-10-07	Искусственный ген Stbl_RBD_TrM_SC2, кодирующий бицистронную структуру, образованную последовательностями рецепторсвязывающего домена гликопротеина S коронавируса SARS-CoV-2, трансмембранного региона, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_TrM_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_TrM_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
Hahn et al.	1992	Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation.
Jeffers et al.	2002	Covalent modifications of the ebola virus glycoprotein
Ciminale et al.	1995	Expression and characterization of proteins produced by mRNAs spliced into the X region of the human T-cell leukemia/lymphotropic virus type II
Vincent et al.	1998	Function of the KKXX motif in endoplasmic reticulum retrieval of a transmembrane protein depends on the length and structure of the cytoplasmic domain
ATE352636T1 (de)	2007-02-15	Auf dem rinderimmunschwächevirus (biv) basierte vektoren
DE69829471D1 (de)	2005-04-28	Auf lentivirus basierende gentransfer-vektoren
McGettigan et al.	2003	Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome
CA2370103A1 (en)	2000-11-09	Method and means for producing high titer, safe, recombinant lentivirus vectors
DK1792997T3 (da)	2012-01-30	Lentiviral triplex DNA og vektorer og rekombinante celler indeholdende lentiviralt triplex DNA
JP2005502355A5 (de)	2008-11-27
SG55158A1 (en)	1998-12-21	Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
Schwartz et al.	1997	Distinct functions and requirements for the Cys-His boxes of the human immunodeficiency virus type 1 nucleocapsid protein during RNA encapsidation and replication
Dash et al.	1994	Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion
Bobkova et al.	2002	Identification of R-peptides in envelope proteins of C-type retroviruses
ATE293171T1 (de)	2005-04-15	Retrovirale, mit lcmv-glykoprotein pseudotypisierte hybrid-vektoren
ATE258987T1 (de)	2004-02-15	Helfersystem zur wirkungssteigerung der aav- vektorproduktion
JP2004524805A5 (de)	2011-10-13
Du et al.	2010	Efficient replication and generation of recombinant bovine adenovirus‐3 in nonbovine cotton rat lung cells expressing I‐SceI endonuclease
Bukrinskaya et al.	1992	HIV-1 matrix protein p17 resides in cell nuclei in association with genomic RNA
Gaudin et al.	1999	Soluble ectodomain of rabies virus glycoprotein expressed in eukaryotic cells folds in a monomeric conformation that is antigenically distinct from the native state of the complete, membrane-anchored glycoprotein
Kobayashi et al.	2000	Translation initiation of a bicistronic mRNA of Borna disease virus: a 16-kDa phosphoprotein is initiated at an internal start codon